Galunisertib

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Galunisertib
Galunisertib.svg
Clinical data
Routes of
administration
PO
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H19N5O
Molar mass369.428 g·mol−1
3D model (JSmol)

Galunisertib (LY2157299) is a small molecular experimental cancer drug in development by Eli Lilly. It is a TGF-b inhibitor.[1]

Galunisertib is in a phase II trial for treatment of hepatocellular carcinoma.[2] Combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition.[3]

References[edit]

  1. ^ "Lilly Oncology Pipeline - Lilly USA". www.lillyoncologypipeline.com.
  2. ^ "A Study of LY2157299 in Participants With Hepatocellular Carcinoma - Full Text View - ClinicalTrials.gov".
  3. ^ Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., ... & Surguladze, D. (2018). Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Journal for immunotherapy of cancer, 6(1), 47. doi:10.1186/s40425-018-0356-4 PMC 5987416